[1. Paterson JM, Mamdani M, Juurlink DN, Naglie G, Laupacis A, Stukel TA. Clinical consequences of generic warfarin substitution: an ecological study. JAMA. 2006; 296:1969-72. DOI: 10.1001/jama.296.16.1969-b10.1001/jama.296.16.1969-b17062858]Search in Google Scholar
[2. Borobia AM, Lubomirov R, Ramírez E, Lorenzo A, Campos A, Mu-oz-Romo R, et al. An Acenocoumarol Dosing Algorithm Using Clinical and Pharmacogenetic Data in Spanish Patients with Thromboembolic Disease. PLoS One. 2012;7(7):e41360. DOI: 10.1371/ journal.pone.004136010.1371/journal.pone.0041360340117222911785]Search in Google Scholar
[3. Gadisseur APA, van der Meer FJM, Adriaansen HJ, Fihn SD, Rosendaal FR. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol. 2002 Jun;117(4):940-6. DOI: 10.1046/j.1365-2141.2002.03493.x10.1046/j.1365-2141.2002.03493.x12060134]Search in Google Scholar
[4. Poller L. Interrnational Normalized Ratios (INR): the first 20 years. J Thromb Haemost. 2004;2:849-60. DOI: 10.1111/j.1538-7836.2004.00775.x10.1111/j.1538-7836.2004.00775.x15140114]Search in Google Scholar
[5. Biss TT, Avery PJ, Walsh PM, Kamali F. Comparison of ‚time within therapeutic INR range’ with ‚percentage INR within therapeutic range’ for assessing longterm anticoagulation control in children. J Thromb Haemost. 2011;9:1090-2. DOI: 10.1111/j.1538-7836.2011.04500.x10.1111/j.1538-7836.2011.04500.x21899719]Search in Google Scholar
[6. Gatt A, Van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost. 2008;100:350-5. DOI: 10.1160/th07-05-035710.1160/TH07-05-0357]Search in Google Scholar
[7. Gatt A, Riddel A, Van Veen JJ, Kitchen S, Tuddenham EG, Makris M. Optimizing warfarin reversal - an ex vivo study. J Thromb Haemost. 2009;7(7):1123-7. DOI: 10.1111/j.1538-7836.2009.03435.x10.1111/j.1538-7836.2009.03435.x19575759]Search in Google Scholar
[8. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral Anticoagulant Therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2):e44S-e88S.10.1378/chest.11-2292327805122315269]Search in Google Scholar
[9. Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, Brensinger CM, Newcomb CW, Samaha FF, Gross R. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med. 2007;167(3):229-35. DOI: 10.1001/archinte.167.3.22910.1001/archinte.167.3.22917296877]Search in Google Scholar
[10. Orensky IA, Holdford DA. Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy. 2005;25(12):1801-8. DOI: 10.1592/phco.2005.25.12.180110.1592/phco.2005.25.12.180116305299]Search in Google Scholar
[11. Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf. 2008;17(9):853-60. DOI: 10.1002/pds.155610.1002/pds.1556]Search in Google Scholar
[12. Shepherd AM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol. 1977;4(3):315-20. DOI: 10.1111/ j.1365-2125.1977.tb00719.x10.1111/j.1365-2125.1977.tb00719.x]Search in Google Scholar
[13. Gurwitz JH, Avorn J,Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the Anticoagulant Response to Warfarin Therapy. Ann Intern Med. 1992;116(11):901-4. DOI: 10.7326/0003-4819-116-11-90110.7326/0003-4819-116-11-901]Search in Google Scholar
[14. El-Helou N, Al-Hajje A, Ajrouche R, Awada S, Rachidi S, Zein S, et al. Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance. Vasc Health Risk Manag. 2013;9:81-8.]Search in Google Scholar
[15. Martin JH. Pharmacogenetics of warfarin - is testing clinically indicated? Aust Prescr. 2009;32:76-80.]Search in Google Scholar
[16. Shibata Y, Hashimoto H, Kurata C, Ohno R, Kazui T, Takinami M. Influence of physical activity on warfarin therapy. Thromb Haemost. 1998; 80(1):203-4.]Search in Google Scholar
[17. Lenz TL, Lenz NJ, Faulkner MA. Potential interactions between exercise and drug therapy. Sports Med. 2004;34(5):293-306. DOI: 10.2165/00007256-200434050-0000210.2165/00007256-200434050-00002]Search in Google Scholar
[18. Weathermon R, Crabb DW. Alcohol and medication interactions. Alcohol Res Health. 1999;23(1):40-54.]Search in Google Scholar
[19. Booth SL, Suttie JW. Dietary Intake and Adequacy of Vitamin K. J Nutr. 1998;128(5):785-8.10.1093/jn/128.5.785]Search in Google Scholar
[20. Booth SL, Pennington JAT, Sadowski JA. Food sources and dietary intakes of vitamin K1 (phylloquinone) in the American diet: data from the FDA Total Diet Study. J Am Diet Assoc. 1996;96:149-54. DOI: 10.1016/ S0002-8223(96)00044-210.1016/S0002-8223(96)00044-2]Search in Google Scholar
[21. Price R, Fenton S, Shearer MJ, Bolton-Smith C. Daily and seasonal variation in phylloquinone (vitamin K1) intake in Scotland. Proc Nutr Soc. 1996;55:244.]Search in Google Scholar
[22. Rombouts EK, Rosendaal FR, Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost. 2007;5:2043-8. DOI: 10.1111/j.1538-7836.2007.02715.x10.1111/j.1538-7836.2007.02715.x17666020]Search in Google Scholar
[23. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007; 109:2419-23. DOI: 10.1182/ blood-2006-09-04926210.1182/blood-2006-09-04926217110451]Search in Google Scholar
[24. de Assis MC, Rabelo ER, Ávila CW, Polanczyk CA, Rohde LE, Improved Oral Anticoagulation After a Dietary Vitamin K-Guided Strategy. A Randomized Controlled Trial. Circulation. 2009;120:1115-22. DOI: 10.1161/CIRCULATIONAHA.109.84920810.1161/CIRCULATIONAHA.109.84920819738137]Search in Google Scholar
[25. Beatty SJ, Mehta BH, Rodis JL. Decreased warfarin effect after initiation of high-protein, low-carbohydrate diets. Ann Pharmacother. 2005;39(4):744-7. DOI: 10.1345/aph.1E45410.1345/aph.1E45415755790]Search in Google Scholar
[26. Hornsby LB, Hester EK, Donaldson AR. Potential interaction between warfarin and high dietary protein intake. Pharmacotherapy. 2008;28(4):536-9. DOI: 10.1592/phco.28.4.53610.1592/phco.28.4.536]Search in Google Scholar
[27. Paoletti A, Gallo E, Benemei S, Vietri M, Alfredo Vannacci, et al. Interactions between Natural Health Products and Oral Anticoagulants: Spontaneous Reports in the Italian Surveillance System of Natural Health Products. Evidence-Based Complementary and Alternative Medicine 2011(2011), Article ID 612150, 5 pages.]Search in Google Scholar
[28. Olson RE. Vitamin K. In: Shils M, Olson JA, Shike M, Ross AC, eds. Modern Nutrition in Health and Disease. 9th ed. Baltimore: Lippincott Williams & Wilkins. 1999:363-80.]Search in Google Scholar
[29. Traber MG. Vitamin E and K interactions-a 50-yearold problem. Nutr Rev. 2008;66(11):624-9. DOI: 10.1111/j.1753-4887.2008.00123.x10.1111/j.1753-4887.2008.00123.x]Search in Google Scholar
[30. Knudsen JF, Sokol GH. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. Pharmacotherapy. 2010;30(1):110.]Search in Google Scholar
[31. Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of Concurrent Use of Warfarin with Potentially Interacting Drugs. Pharmacotherapy 2004;24:1668-74. DOI: 10.1592/ phco.24.17.1668.5233810.1592/phco.24.17.1668.52338]Search in Google Scholar
[32. Gebauer MG, Nyfort-Hansen K, Henschke PJ, Gallus AS. Warfarin and acetaminophen interaction. Pharmacotherapy 2003;23(1):109-12. DOI: 10.1592/ phco.23.1.109.3191310.1592/phco.23.1.109.31913]Search in Google Scholar
[33. Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am. 1992;6(6):1247-57.10.1016/S0889-8588(18)30273-9]Search in Google Scholar
[34. Sawicka-Powierza J, Rogowska-Szadkowska D, Ołtarzewska AM, Chlabicz S. Factors influencing activity of oral anticoagulants. Interactions with drugs and food. Pol Merkur Lekarski. 2008;24(143):458-62.]Search in Google Scholar
[35. Rettie A, Tai G. Pharmacogenomics of warfarin metabolism. Molecular Interventions. 2006;6(4):223-7. DOI: 10.1124/mi.6.4.810.1124/mi.6.4.8]Search in Google Scholar
[36. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001;11(9):803-8. DOI: 10.1097/00008571-200112000-0000810.1097/00008571-200112000-00008]Search in Google Scholar
[37. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, et al. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006;16(7):497-514. DOI: 10.1097/01. fpc.0000215069.14095.c610.1097/01]Search in Google Scholar
[38. Muszkat M, Blotnik S, Elami A, Krasilnikov I, Caraco Y. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Clin Ther. 2007;29(3):427-37. DOI: 10.1016/S0149-2918(07)80081-610.1016/S0149-2918(07)80081-6]Search in Google Scholar
[39. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation of warfarin dose. N Engl J Med. 2005;352:2285-93. DOI: 10.1056/NEJMoa04450310.1056/NEJMoa04450315930419]Search in Google Scholar
[40. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004 Feb 5;427(6974):537-41. DOI: 10.1038/nature0221410.1038/nature0221414765194]Search in Google Scholar
[41. D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticogulant effect of warfarin. Blood. 2005 Jan 15;105(2):645-9. DOI: 10.1182/ blood-2004-06-211110.1182/blood-2004-06-211115358623]Search in Google Scholar
[42. Sinxadi P, Blockman M. Warfarin resistance. Cardiovasc J Afr. 2008;19(4):215-7.]Search in Google Scholar
[43. Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, et al. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res. 2007;5:8-16. DOI: 10.3121/cmr.2007.72410.3121/cmr.2007.724185534017456829]Search in Google Scholar
[44. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329-33. DOI: 10.1182/ blood-2005-03-110810.1182/blood-2005-03-110815947090]Search in Google Scholar
[45. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011 Oct;90(4):625-9. DOI: 10.1038/ clpt.2011.18510.1038/clpt.2011.185318755021900891]Search in Google Scholar
[46. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A Randomized Trial of Genotype-Guided Dosing of Warfarin. N Engl J Med. 2013;369:2294-303. DOI: 10.1056/NEJMoa131138610.1056/NEJMoa131138624251363]Search in Google Scholar
[47. Stergiopoulos K, Brown DL. Genotype-Guided vs Clinical Dosing of Warfarin and Its Analogues Meta- analysis of Randomized Clinical Trials. JAMA Intern Med. 2014;174(8):1330-8. DOI: 10.1001/jamainternmed. 2014.2368]Search in Google Scholar
[48. Bauer KA. Pros and cons of new oral anticoagulants. ASH Education Book. 2013;2013(1):464-70. DOI: 10.1182/asheducation-2013.1.464 10.1182/asheducation-2013.1.46424319220]Search in Google Scholar